Table 2.

Characteristics of JHU cohort diagnosed between January 1994 and September 2011, treated with RP, and observed to have PSA recurrence

All cases (n = 1,071)No salvage therapy (N = 441)Salvage therapy (n = 604)
CharacteristicsNo. of patientsPercentageNo. of patientsPercentageNo. of patientsPercentage
Age at diagnosis (y)
 40–49827.7306.8528.6
 50–5948745.520346.027445.4
 60–6948044.819544.226944.5
 ≥70212.0133.081.3
Year of diagnosis
 1994–199622921.41069.912311.5
 1997–199922721.2898.313812.9
 2000–200222821.3979.113112.2
 2003–200517216.1746.9989.2
 2006–200814813.8615.7878.1
 2009–2012413.8141.3272.5
RP GS
 ≤622821.312027.210417.2
 760156.123854.035358.4
 ≥824222.68318.814724.2
PSA at diagnosis, ng/mL
 0–2.5312.9143.2142.3
 2.51–4797.4368.2427.0
 4.1–6.028726.811526.116627.5
 6.1–10.036133.714633.120533.9
 ≥1031329.213029.517729.3
Pathologic stage
 ≤T2a30128.113229.916226.8
 >T2a77071.930970.144273.2
Time to PSA recurrence, y
 ≤367062.625156.939665.6
 >340137.419043.120834.4